Payment overview · 2025
General Payments
$236.32
12 reported records · 11 companies
Healthcare provider profile · identity verified
Christopher Edward Baur, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FAYETTEVILLE, GA · NPI 1417913591
Verified facts
What the public records show
CMS Open Payments records show Christopher Edward Baur, M.D. received $236.32 in general payments during 2025 across 12 reported records.
Corcept Therapeutics accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Rexulti, Shingrix.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $40.61 | 17.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.76 | 12.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.02 | 9.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.97 | 9.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.21 | 9.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.30 | 9.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.76 | 7.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.69 | 6.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.39 | 6.5% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $14.96 | 6.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $13.65 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $236.32 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $51.06 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $40.61 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 190 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 173 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
173 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
173 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 662 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 498 | 121 |
| Lisinopril | Lisinopril | 479 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 366 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 67 |
| Gabapentin | Gabapentin | 254 | 61 |
| Potassium Chloride | Potassium Chloride | 250 | 30 |
| Furosemide | Furosemide | 241 | 45 |
| Losartan Potassium | Losartan Potassium | 225 | 55 |
| Eliquis | Apixaban | 190 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 59 |
| Metformin Hcl | Metformin Hcl | 178 | 39 |
| Jardiance | Empagliflozin | 173 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 171 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 24 |
| Omeprazole | Omeprazole | 169 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 44 |
| Donepezil Hcl | Donepezil Hcl | 156 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 156 | 33 |
| Entresto | Sacubitril/Valsartan | 149 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 34 |
| Famotidine | Famotidine | 131 | 36 |
| Allopurinol | Allopurinol | 130 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 17 |
| Carvedilol | Carvedilol | 128 | 27 |
| Tramadol Hcl | Tramadol Hcl | 128 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 33 |
| Spironolactone | Spironolactone | 119 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 118 | 24 |
| Trazodone Hcl | Trazodone Hcl | 112 | 35 |
| Bupropion Xl | Bupropion Hcl | 111 | 24 |
| Ozempic | Semaglutide | 111 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 35 |
| Metformin Hcl Er | Metformin Hcl | 108 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 31 |
| Memantine Hcl | Memantine Hcl | 92 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 92 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 44 |
| Alendronate Sodium | Alendronate Sodium | 91 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 24 |
| Meloxicam | Meloxicam | 86 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 19 |
| Montelukast Sodium | Montelukast Sodium | 73 | 14 |
| Farxiga | Dapagliflozin Propanediol | 67 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 63 | 11 |
| Olanzapine | Olanzapine | 61 | suppressed |
| Celecoxib | Celecoxib | 60 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 20 |
| Diazepam | Diazepam | 54 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 14 |
| Rexulti | Brexpiprazole | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | 11 |
| Labetalol Hcl | Labetalol Hcl | 52 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 50 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Finasteride | Finasteride | 49 | 15 |
| Chlorthalidone | Chlorthalidone | 48 | 11 |
| Topiramate | Topiramate | 48 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 13 |
| Novolog Flexpen | Insulin Aspart | 43 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Alprazolam | Alprazolam | 39 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 38 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Simvastatin | Simvastatin | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Prednisone | Prednisone | 34 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 14 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 16 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $236.32 · 12 records | Corcept Therapeutics | ACCRUFER, AREXVY, CAPLYTA, CT THROMBECTOMY SYSTEM KIT, ELIQUIS, FLOWTRIEVER CATHETER, S, Fluad, Flucelvax, INTERSTIM, JARDIANCE, Korlym, NURTEC ODT, REXULTI, SHINGRIX | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error